Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 2003;76(2):55–62.

The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma.

Dong-Dong Lu 1, Yi-Cun Chen 1, Xi-Ran Zhang 1, Xiang-Rong Cao 1, Hua-Yun Jiang 1, Lin Yao 1
PMCID: PMC2582696  PMID: 15369632

Abstract

To investigate the expression of MT1F gene in hepatocellular carcinoma tissue and the growth suppression effect of exogenous introduction of MT1F gene on liver cell line HepG2 and to explore the potential application of MT1F gene in gene therapy of tumor. Eukaryotic expression vector of pCMV-MT1F plasmid was introduced into HepG2 line which expressed no MT1F protein originally with lipofectamine transfection method. The cell growth curve, soft agar colony formation rate and tumorigenicity in SCID mice were examined to demonstrate the growth suppression effect of exogenous MT1F gene on HepG2 cell line. The MT1F mRNA and MT1F protein were also detected in 60 pairs of surgical specimens of hepatocellular carcinoma by in situ hybridization and immunohistochemistry. The transfected HepG2 cell line grew more slowly than control HepG2 as shown by cell growth curves, the soft agar colony formation rate (3.8 percent vs. 7.4 percent, p <.01) and the average growth rate of tumor in SCID mice (30.9 +/- 6.9 vs. 70.3 +/- 5.6, p <.01). The expression level of MT1F mRNA and protein significantly increased in paracancerous tissue, normal tissue than in cancer tissues (75 percent, 70 percent vs. 16.7 percent by ISH and 66.7 percent, 60 percent vs. 10 percent by IHC, p <.01). Exogenous MT1F gene shows the strong effect of growth inhibition on HepG2 cell line. In the liver cancer tissue, MT1F shows down-regulated expression that supports the inhibited function of MT1F in cancer growth and suggests MT1F may have an important role in gene therapy of hepatocellular carcinoma.

Full text

PDF
55

Images in this article

58Figure 1
on p.58
58Figure 2
on p.58
59Figure 4
on p.59

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abou-Shady M., Baer H. U., Friess H., Berberat P., Zimmermann A., Graber H., Gold L. I., Korc M., Büchler M. W. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg. 1999 Mar;177(3):209–215. doi: 10.1016/s0002-9610(99)00012-4. [DOI] [PubMed] [Google Scholar]
  2. Carloni V., Mazzocca A., Pantaleo P., Cordella C., Laffi G., Gentilini P. The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. Hepatology. 2001 Jul;34(1):42–49. doi: 10.1053/jhep.2001.25224. [DOI] [PubMed] [Google Scholar]
  3. De Miglio M. R., Muroni M. R., Simile M. M., Virdis P., Asara G., Frau M., Calvisi D. F., Seddaiu M. A., Pascale R. M., Feo F. Frequent loss of heterozygosity at the Hcr1 (hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain. Hepatology. 2001 May;33(5):1110–1117. doi: 10.1053/jhep.2001.23795. [DOI] [PubMed] [Google Scholar]
  4. Factor V., Oliver A. L., Panta G. R., Thorgeirsson S. S., Sonenshein G. E., Arsura M. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. Hepatology. 2001 Jul;34(1):32–41. doi: 10.1053/jhep.2001.25270. [DOI] [PubMed] [Google Scholar]
  5. Han S. Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., Matsuno S., Kanamaru R., Ishioka C. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 2000 Jun 15;60(12):3147–3151. [PubMed] [Google Scholar]
  6. Kagawa S., Gu J., Swisher S. G., Ji L., Roth J. A., Lai D., Stephens L. C., Fang B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res. 2000 Mar 1;60(5):1157–1161. [PubMed] [Google Scholar]
  7. Kawamura N., Nagai H., Bando K., Koyama M., Matsumoto S., Tajiri T., Onda M., Fujimoto J., Ueki T., Konishi N. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res. 1999 Apr;90(4):413–418. doi: 10.1111/j.1349-7006.1999.tb00763.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Koike Y., Shiratori Y., Sato S., Obi S., Teratani T., Imamura M., Hamamura K., Imai Y., Yoshida H., Shiina S. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology. 2000 Dec;32(6):1216–1223. doi: 10.1053/jhep.2000.20237. [DOI] [PubMed] [Google Scholar]
  9. Lise M., Bacchetti S., Da Pian P., Nitti D., Pilati P. L., Pigato P. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer. 1998 Mar 15;82(6):1028–1036. doi: 10.1002/(sici)1097-0142(19980315)82:6<1028::aid-cncr4>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  10. Nagai H., Ponglikitmongkol M., Fujimoto J., Yamamoto H., Kim Y. S., Konishi N., Matsubara K. Genomic aberrations in early stage human hepatocellular carcinomas. Cancer. 1998 Feb 1;82(3):454–461. [PubMed] [Google Scholar]
  11. Nalesnik M. A., Lee R. G., Carr B. I. Transforming growth factor alpha (TGFalpha) in hepatocellular carcinomas and adjacent hepatic parenchyma. Hum Pathol. 1998 Mar;29(3):228–234. doi: 10.1016/s0046-8177(98)90040-5. [DOI] [PubMed] [Google Scholar]
  12. Raunio H., Juvonen R., Pasanen M., Pelkonen O., Päkkö P., Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology. 1998 Feb;27(2):427–432. doi: 10.1002/hep.510270217. [DOI] [PubMed] [Google Scholar]
  13. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H., Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology. 2001 Mar;33(3):561–568. doi: 10.1053/jhep.2001.22507. [DOI] [PubMed] [Google Scholar]
  14. Tannapfel A., Wasner M., Krause K., Geissler F., Katalinic A., Hauss J., Mössner J., Engeland K., Wittekind C. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999 Jul 7;91(13):1154–1158. doi: 10.1093/jnci/91.13.1154. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES